Research and Markets: Biosimilars Advisory Service: Physician Perspectives on Biosimilar G-CSFs and MAbs in Oncology
Research and Markets (http://www.researchandmarkets.com/research/ftdxm6/biosimilars) has announced the addition of Decision Resources, Inc's new report "Biosimilars Advisory Service: Physician Perspectives on Biosimilar G-CSFs and MAbs in Oncology" to their offering.
Monoclonal antibodies (MAbs) in oncology are highly commercially successful2010 sales of major MAbs (rituximab [Biogen Idec/Roche/Chugai/Zenyaku Kogyo's Rituxan/MabThera], trastuzumab [Roche/Genentech/Chugai's Herceptin], cetuximab [Bristol-Myers Squibb/ImClone/Eli Lilly/Merck Serono's Erbitux], and bevacizumab [Roche/Genentech/Chugai's Avastin]) across the seven major pharmaceutical markets that we cover (United States, EU5 [France, Germany, Italy, Spain, United Kingdom], and Japan) reached nearly $15 billion, making them a prime target for biosimilars manufacturers.
Combined sales of granulocyte colony-stimulating factors (G-CSFs) (Amgen's Neupogen [filgrastim] and Neulasta [pegfilgrastim]) were approximately $4.6 billion in 2010 despite active biosimilar competition in Europe for filgrastim. Over the course of our 2010-2020 forecast period, we anticipate biosimilar MAbs will gain the second-highest commercial reward of any of the biosimilar classes expected to be on the market. Although market share for biosimilar MAbs in oncology will not reach the same depth of penetration expected for biosimilar G-CSFs, biosimilar versions of G-CSFs will be less commercially successful based on the lower brand sales forecasts through 2020.
Nevertheless, newly launching biosimilar versions of G-CSFs and MAbs will save healthcare systems $3.8 billion in 2020 across the seven pharmaceutical markets. Total sales across the major pharmaceutical markets for biosimilar G-CSFs and MAbs are forecast to reach in excess of $6.5 billion in 2020.
The primary research presented in this report is gathered from a quantitative, online, 40-minute survey with 76 solid-tumor oncologists and 78 hematologist-oncologists from the United States, France, and Germany.
Key Topics Covered:
1. Key Findings
2. Introduction and Methodology
3. Oncologist Perspectives
Current Reimbursement of Biologics in Oncology
Current Understanding of Biosimilars
Expectations for Biosimilar Trials
Attitudes of Key Stakeholders
Anticipated Initial Use of Biosimilars
Eventual Use of Biosimilars
Reasons for Current Slow Adoption of Biosimilars
4. Market Forecast
Overview of Biosimilar Erosion Across Major Markets
Branded and Biosimilar G-CSFs
Branded and Biosimilar MAbs
For more information visit http://www.researchandmarkets.com/research/ftdxm6/biosimilars
Source: Decision Resources, Inc